Veeva Systems, Inc. (NYSE:VEEV) is a cloud-computing company focused on delivering software solutions tailored to the life sciences industry. Founded in 2007 by Peter Gassner and a team of industry veterans, Veeva offers a suite of applications designed to streamline clinical, regulatory, quality, and commercial operations for pharmaceutical, biotechnology, and medical device organizations. Its software-as-a-service (SaaS) model enables companies to manage content, data, and business processes in a secure, compliant environment.
The company’s flagship offering, Veeva Vault, provides a cloud-based content management platform that supports a wide range of functions such as clinical trial operations, regulatory submissions, quality management, and safety management. Veeva CRM, another core product, equips commercial teams with customer relationship management tools optimized for healthcare professionals and key accounts. Additional solutions include Veeva Network for master data management, Veeva Nitro for life sciences data analytics, and Veeva OpenData for global healthcare professional and organization reference data.
With headquarters in Pleasanton, California, Veeva has expanded its global footprint through offices in North America, Europe, Asia Pacific, Latin America, and Japan. The company serves thousands of customers ranging from large multinational pharmaceutical firms to emerging biotech companies. Its industry-specific focus allows Veeva to incorporate regulatory guidance and best practices directly into its applications, helping clients accelerate drug development, ensure product quality, and optimize commercial performance on a global scale.
Under the leadership of CEO Peter Gassner and a seasoned executive team, Veeva has maintained a strong commitment to innovation and customer success. The company invests heavily in research and development to extend its platform capabilities, often partnering with life sciences organizations to address emerging challenges such as digital regulatory submissions and real-world evidence generation. Since its initial public offering in 2013, Veeva has grown both organically and through strategic acquisitions, reinforcing its position as a leading provider of cloud software for the life sciences sector.
AI Generated. May Contain Errors.
